The Arizona Legislature has voted to approve a plan to invest $1 Billion in Arizona’s University Research Infrastructure.
Continue reading
Category Archives: AZBio News
Critical Path Institute and TGen forge partnership to advance TB research
TUCSON and FLAGSTAFF, Ariz. — May 1, 2017 — The Critical Path to TB Drug Regimens (CPTR), an initiative of the Critical Path Institute (C-Path), has received a $1.1 million grant from the Bill & Melinda Gates Foundation to significantly enrich its Relational Sequencing TB Data Platform (ReSeqTB).
HealthTell, Inc. Launches New Pre-Clinical Services Business
An Efficient, Information Rich, High-Throughput Platform to Characterize Antibodies, with a Vision for New Drug Discovery
Axolotl Biologix Launches AxoBioMembrane™ to Expand Amnion-Derived Allograft Products for Wound Care
Axolotl Biologix, an innovator in regenerative medicine technologies that improve patient outcomes with less pain and lower costs, today announced that it has begun shipping its second amniotic allograft product, AxoBioMembrane™, to meet a wide range of wound care needs.Continue reading
Castle Biosciences’ DecisionDx-Melanoma Test Accurately Predicts Metastatic Risk in Patients with Head and Neck Melanoma
Data was presented at the American College of Mohs Surgery 49th Annual Meeting
Distinguished Cardiologist and Scientist Dr. Guy Reed Named Dean of the UA College of Medicine – Phoenix
Dr. Reed brings impressive record of leadership, teaching, research and clinical careContinue reading
TGen-HonorHealth study: High rate of tumor shrinkage among pancreatic cancer patients
Results of the Triplet Clinical Trial at HonorHealth Research Institute based on the TGen Triple research presented at ASCO-GI symposium in San FranciscoContinue reading
BD To Acquire Bard For $24 Billion
On on April 23, 2017, BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and C. R. Bard, Inc. (NYSE: BCR), a medical technology leader in the fields of vascular, urology, oncology and surgical specialty products, announced a definitive agreement under which BD will acquire Bard for $317.00 per Bard common share in cash and stock, for a total consideration of $24 billion. The agreement has been unanimously approved by the Boards of Directors of both companies.Continue reading